EA202191079A1 - Способы лечения синдрома ретта с применением фенфлурамина - Google Patents

Способы лечения синдрома ретта с применением фенфлурамина

Info

Publication number
EA202191079A1
EA202191079A1 EA202191079A EA202191079A EA202191079A1 EA 202191079 A1 EA202191079 A1 EA 202191079A1 EA 202191079 A EA202191079 A EA 202191079A EA 202191079 A EA202191079 A EA 202191079A EA 202191079 A1 EA202191079 A1 EA 202191079A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fenfluramine
day
syndrome
patient
retta
Prior art date
Application number
EA202191079A
Other languages
English (en)
Inventor
Брэдли С. Гэйлер
Брет Мегарджел
Original Assignee
Зодженикс Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зодженикс Интернэшнл Лимитед filed Critical Зодженикс Интернэшнл Лимитед
Publication of EA202191079A1 publication Critical patent/EA202191079A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Способ лечения и/или профилактики симптомов синдрома Ретта (RTT) у пациента, такого как пациент, у которого ранее был диагностирован синдром Ретта, путем введения эффективной дозы агониста рецепторов 5-HT1D, 5-HT2A, 5-HT2C или сигма-1 (например, фенфлурамина или его фармацевтически приемлемой соли) этому пациенту. Пациентов с RTT лечат предпочтительной дозой менее приблизительно 1,0 мг/кг/день, и можно вводить в виде фенфлурамина в количестве от 0,2 до 0,8 мг/кг/день, максимум 30 мг/день в форме жидкой дозы для перорального введения.
EA202191079A 2018-11-19 2019-11-22 Способы лечения синдрома ретта с применением фенфлурамина EA202191079A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862769441P 2018-11-19 2018-11-19
PCT/IB2019/060067 WO2020105005A1 (en) 2018-11-19 2019-11-22 Methods of treating rett syndrome using fenfluramine

Publications (1)

Publication Number Publication Date
EA202191079A1 true EA202191079A1 (ru) 2021-09-20

Family

ID=68808446

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191079A EA202191079A1 (ru) 2018-11-19 2019-11-22 Способы лечения синдрома ретта с применением фенфлурамина

Country Status (7)

Country Link
US (1) US20220008389A1 (ru)
EP (1) EP3883555A1 (ru)
AU (3) AU2019384963B2 (ru)
CA (1) CA3117868A1 (ru)
EA (1) EA202191079A1 (ru)
SG (1) SG11202104378SA (ru)
WO (1) WO2020105005A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804811WA (en) 2015-12-22 2018-07-30 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
AU2016379345B2 (en) 2015-12-22 2020-09-17 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
JP2019526544A (ja) 2016-08-24 2019-09-19 ゾゲニクス インターナショナル リミテッド ５−ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
GB2597314A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597321A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
WO2010020585A1 (en) * 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
US9682948B2 (en) 2012-11-05 2017-06-20 Emory University 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
AU2016312526B2 (en) * 2015-08-24 2021-09-09 Zogenix International Limited Methods of treating lennox-gastaut syndrome using fenfluramine
SG11201804811WA (en) 2015-12-22 2018-07-30 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
EP3790537A1 (en) * 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death

Also Published As

Publication number Publication date
EP3883555A1 (en) 2021-09-29
AU2019384963B2 (en) 2022-05-26
US20220008389A1 (en) 2022-01-13
AU2022221450A1 (en) 2022-09-22
AU2022221450B2 (en) 2024-04-11
WO2020105005A1 (en) 2020-05-28
AU2024202885A1 (en) 2024-05-23
SG11202104378SA (en) 2021-05-28
CA3117868A1 (en) 2020-05-28
AU2019384963A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
EA202090932A1 (ru) Способы введения некоторых vmat2-ингибиторов
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
ATE293451T1 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
JP2020500864A5 (ru)
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
JP2016512247A5 (ru)
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
JP2016505050A5 (ru)
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.
Toyofuku Efficacy of milnacipran for glossodynia patients